Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pexacerfont
BMS-562086 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | PLACEBO_COMPARATOR | - |
| 1 | OTHER | 0 mg |
| 2 | OTHER | 25 mg |
| 3 | OTHER | 100 mg |
| Name | Type | Description |
|---|---|---|
| pexacerfont | DRUG | Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks |
| escitalopram | DRUG | Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks |
| placebo | DRUG | Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks |
| BMS-562086 | DRUG | Tablets, Oral, once daily, 2 weeks |
Inclusion Criteria: * Outpatient women ages 18-65 meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for Generalized Anxiety Disorder (GAD), either moderate or severe (300.02) Exclusion Criteria: * Males * Patients who report a...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 2 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE2 | LY3537031 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | Camlipixant |
BMS-562086 is an investigational small molecule being studied for the treatment of irritable bowel syndrome (IBS). It is in Phase 2 clinical development and has been evaluated in a completed clinical trial involving female patients with IBS in the United States.
BMS-562086 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research on this investigational drug for irritable bowel syndrome.
BMS-562086 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with irritable bowel syndrome.
BMS-562086 has been studied in a completed Phase 2 clinical trial identified as NCT00399438, titled "A Study of BMS-562086 in Patients With Irritable Bowel Syndrome." This randomized, double-blind, controlled trial enrolled 39 female participants aged 18 years and older in the United States.
Yes, BMS-562086 is a small molecule drug. It is being developed as an oral therapeutic for gastrointestinal conditions, specifically irritable bowel syndrome, and is currently in Phase 2 clinical testing.